Tecentriq Adds 38% to the Time It Takes for Lung Cancer to Progress, Trial Shows
Lung Cancer, News
Adding Genentech’s Tecentriq (atezolizumab) to a combination of Avastin and chemotherapy led to lung cancer patients living 38 percent longer before their disease progressed or they died, a Phase 3 trial shows. The ... Read more